2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Pathology, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Checkpoint Inhibitor, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, LGL, Non-Hodgkin Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult
PAPER

5366 T-cell post-transplant lymphoproliferative disorder: A rare and aggressive entity

Omar Elghawy, MD, Ahmed Gawash, DO2, Colin J. Thomas, MD3, Arianne Rizi4, Kimberly Carlton, RN5, Jordan S Carter, MD6, Elise A. Chong, MD7, Daniel Landsburg, MD8, Joshua D Brandstadter, MD,PhD,MSc9, Michael R Cook, MD10, Stephen J Schuster, MD11, Jakub Svoboda, MD12, Emily B. Tomasulo, DO13, Sunita Dwivedy Nasta, MD, MS14, Marco Ruella, MD15, Stefan K Barta, MD16
1 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
2 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
3 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
4 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
5 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
6 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
7 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
8 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
9 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
10 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
11 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
12 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
13 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
14 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
15 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States
16 Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States

Background: Post-transplant lymphoproliferative disorder (PTLD) is an uncommon complication of immunosuppression following solid organ transplantation (SOT) or hematopoietic cell transplantation (HCT). While 90–95% of PTLD cases are of B-cell origin, T-cell PTLD (T-PTLD) is rare and remains poorly characterized, with limited data guiding management. We sought to describe the clinical characteristics, treatment patterns, and outcomes of patients (pts) with T-PTLD across transplant populations.

Methods: We performed a single-center retrospective study of pts diagnosed with T-PTLD at the University of Pennsylvania between January 2010 and January 2026.Treatment response was assessed using Lugano criteria, and infections were graded per CTCAE version 5.0. Co-primary endpoints, overall survival (OS) and progression-free survival (PFS), were estimated using Kaplan-Meier methods.

Results: Twenty-six pts with T-PTLD were identified: 65.4% after SOT (kidney 8/17 [47.1%], liver 4/17 [23.5%], heart 3/17 [17.6%], and lung 2/17 [11.8%] of SOT pts; 3 of these 17 pts underwent multi-organ transplantation) and 34.6% after HCT. Median age at diagnosis was 58.2 years (IQR, 44.5–63.6), and median interval from transplant to diagnosis was 49.2 months (IQR, 5.1–111.2). Most pts (65.4%) were male; 73.1% were Caucasian, 19.2% Black, and 7.7% were of unknown race. No pts had a prior diagnosis of HIV or hepatitis B/C, and 11.5% had prior autoimmune disease. Immunosuppressive therapy (IST) at diagnosis included tacrolimus (73.1%), prednisone (50.0%), mycophenolate mofetil (30.8%), azathioprine (23.1%), and sirolimus and ruxolitinib (each 3.8%). Eighteen of 26 pts received combination IST, most commonly tacrolimus + mycophenolate mofetil + prednisone (23.1%).

Most pts had good performance status (ECOG 0–1, 88.5%) despite otherwise high-risk features: stage III/IV disease in 69.2%, B symptoms in 34.6%, bulky disease in 7.7%, elevated LDH in 73.1%, bone marrow involvement in 23.1%, extranodal disease in 65.4%, and poor-risk IPI in 61.5%. Monomorphic PTLD was present in 84.6%, with 15.4% exhibiting polymorphic PTLD. The most common histologic subtypes were peripheral T-cell lymphoma (PTCL) not otherwise-specified (PTCL-NOS) (50.0%) and ALK-negative anaplastic large cell lymphoma (23.1%). We found 66.7% (16/24) were EBV-positive via IHC/EBER-ISH. NGS was performed in 50.0% (13/26), most commonly demonstrating TP53 (4/13, 30.8%), NOTCH pathway (3/13, 23.1%), and DNMT3A/TET2 (2/13, 15.4%) alterations.

Reduction in IST (RIST) was attempted in 80.8% of pts receiving IST. In addition, 88.5% received systemic therapy, with a median time from diagnosis to first treatment of 1.3 months (range, 0–12.5). Frontline approaches included anthracycline-based multiagent chemotherapy (9/23, 39.1%), targeted therapy such as brentuximab vedotin or bexarotene (5/23, 21.7%), and high-dose multiagent chemotherapy (4/23, 17.4%). Rituximab was added for EBV-positive disease in 10/23 (43.5%), and 1/23 (4.3%) proceeded to allogeneic HCT after remission.

The overall response rate was 13/23 (56.5%), including 9/23 (39.1%) complete responses and 4/23 (17.4%) partial responses. After a median follow-up of 25.3 months (range, 0.4–160.4), median PFS was 7.0 months (95% CI, 4.3–13.6) and median OS was 38.3 months (95% CI, 9.2–45.9). Most pts (61.5%) experienced at least one grade ≥3 infection (1 episode in 9/16 [56.3%], 2 episodes in 4/16 [25.0%], and 3 episodes in 3/16 [18.8%]), with maximum severity of grade 3 in 7/16 (43.8%), grade 4 in 5/16 (31.3%), and grade 5 in 4/16 (25.0%). Among the 15 pts with an identified pathogen, infections were bacterial (7/15 [46.7%]), viral (3/15 [20.0%]), fungal (2/15 [13.3%]), or mixed (3/15 [20.0%]). Death occurred in 65.4% of pts: 8/17 (47.1%) from lymphoma, 4/17 (23.5%) from infection, 1/17 (5.9%) from cardiac arrest, and 4/17 (23.5%) from unknown causes. The remaining 34.6% were alive at last follow-up, including 23.1% without evidence of disease.

Conclusions: T-cell PTLD is a rare, aggressive lymphoma that frequently presents with high-risk features and demonstrates poor progression-free survival despite diverse treatment approaches. Strikingly, infectious complications contribute substantially to morbidity and mortality, underscoring the challenge of balancing lymphoma-directed therapy with ongoing immunosuppression. Better treatment strategies remain to be defined for this uncommon PTLD subtype.

Omar Elghawy, MD: No relevant conflicts of interest to declare.